- Ticker
- ADGI
- Price
- 3.48
- Stock movement down
- -0.12 (-3.33%)
- Company name
- Adagio Therapeutics Inc
- Exchange
- (NYSE ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 378.73M
- Ent value
- 147.88M
- Price/Sales
- -
- Price/Book
- 1.00
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -81.82%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2023-03-10
DIVIDENDS
ADGI does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 1.00 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 108.83M |
| EPS (TTM) | -3.09 |
| FCF per share (TTM) | -1.59 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -282.91M |
| Net income (TTM) | -336.76M |
| EPS (TTM) | -3.09 |
| EPS (1y forward) | -1.98 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 278.15M |
| Net receivables | 0.00 |
| Total current assets | 421.60M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 424.75M |
| Accounts payable | 45.74M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 46.13M |
| Total liabilities | 47.30M |
| Shareholder's equity | 377.44M |
| Net tangible assets | 377.44M |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -172.69M |
| Capital expenditures (TTM) | 511.08K |
| Free cash flow (TTM) | -173.18M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -89.22% |
| Return on Assets | -79.29% |
| Return on Invested Capital | -89.22% |
| Cash Return on Invested Capital | -45.88% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 3.55 |
| Daily high | 3.58 |
| Daily low | 3.46 |
| Daily Volume | 269K |
| All-time high | 56.08 |
| 1y analyst estimate | 3.83 |
| Beta | - |
| EPS (TTM) | -3.09 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 29 Mar 2023 |
Downside potential
Loading...
Downside potential data
| ADGI | S&P500 | |
| Current price drop from All-time high | -93.79% | -17.29% |
| Highest price drop | -95.47% | -56.47% |
| Date of highest drop | 16 Jun 2022 | 9 Mar 2009 |
| Avg drop from high | -74.59% | -11.51% |
| Avg time to new high | 21 days | 13 days |
| Max time to new high | 294 days | 1805 days |
COMPANY DETAILS
Marketcap
378.73M
Marketcap category
Small-cap
Description
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
Employees
101
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found